Such agents are mainly bispecific constructs targeting a molecule expressed by tumor cells, enabling CD137-costimulation in cis19,21,22, or by stromal cells in the tumor microenvironment, such as fibroblast activated protein (FAP) enabling CD137-costimulation in trans19. This evidence concerns the gene TNFRSF9 and neoplasm.